These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22579931)

  • 1. Histological assessment of the sclerotic graft-versus-host response in the humanized RAG2-/-γc-/- mouse model.
    Hogenes MC; van Dorp S; van Kuik J; Monteiro FR; ter Hoeve N; van Dijk MR; Martens AC; de Weger RA
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1023-35. PubMed ID: 22579931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.
    Ito R; Katano I; Kawai K; Hirata H; Ogura T; Kamisako T; Eto T; Ito M
    Transplantation; 2009 Jun; 87(11):1654-8. PubMed ID: 19502956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice.
    Mutis T; van Rijn RS; Simonetti ER; Aarts-Riemens T; Emmelot ME; van Bloois L; Martens A; Verdonck LF; Ebeling SB
    Clin Cancer Res; 2006 Sep; 12(18):5520-5. PubMed ID: 17000688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
    Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
    Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
    Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
    PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells].
    Gao L; Wang JM; Xie LN; Zhou H; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):87-91. PubMed ID: 18681307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice.
    Hu Y; Gu Y; Cui Q; Fu H; Sheng L; Wu K; Liu L; Fu S; Yu X; Huang H
    Ann Hematol; 2012 Nov; 91(11):1803-12. PubMed ID: 22699803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
    André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
    J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
    Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice.
    van Rijn RS; Simonetti ER; Hagenbeek A; Hogenes MC; de Weger RA; Canninga-van Dijk MR; Weijer K; Spits H; Storm G; van Bloois L; Rijkers G; Martens AC; Ebeling SB
    Blood; 2003 Oct; 102(7):2522-31. PubMed ID: 12791667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.
    King MA; Covassin L; Brehm MA; Racki W; Pearson T; Leif J; Laning J; Fodor W; Foreman O; Burzenski L; Chase TH; Gott B; Rossini AA; Bortell R; Shultz LD; Greiner DL
    Clin Exp Immunol; 2009 Jul; 157(1):104-18. PubMed ID: 19659776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease.
    Bruck F; Belle L; Lechanteur C; de Leval L; Hannon M; Dubois S; Castermans E; Humblet-Baron S; Rahmouni S; Beguin Y; Briquet A; Baron F
    Cytotherapy; 2013 Mar; 15(3):267-79. PubMed ID: 23265769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine gene expression in peripheral blood mononuclear cells and alloreactivity in hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Dickmeiss E; Vindeløv LL
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):48-60. PubMed ID: 16399568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.
    McCormick LL; Zhang Y; Tootell E; Gilliam AC
    J Immunol; 1999 Nov; 163(10):5693-9. PubMed ID: 10553100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.